---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-046259"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2025-10-24T23:59:59+00:00"
generated_at: "2026-05-17T02:20:48.895087+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arvinas ARV-806 preclinical data: >90% KRAS G12D degradation for 7 days in xenograft models

## Summary
- ARV-806 degraded KRAS G12D with picomolar potency across pancreatic, colorectal, and lung cancer cell lines without affecting wild-type RAS.
- Compared with clinical-stage inhibitors and another G12D degrader, ARV-806 showed >25-fold greater antiproliferative potency and >40-fold higher degradation potency.
- Single dose degraded >90% of KRAS G12D for 7 days in colorectal xenograft, with c-MYC suppression and BIM induction for ≥5 days.
- Achieved ≥30% tumor volume reductions in pancreatic, colorectal CDX and lung PDX models at low doses.
- Phase 1 trial in KRAS G12D-mutated advanced solid tumors (NCT07023731) ongoing; orally bioavailable pan-KRAS degraders also identified.

## SEC filing metadata
- accession: 0001628280-25-046259
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2025-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000162828025046259/0001628280-25-046259-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000162828025046259/arvn-20251024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-046259
- JSON: https://secwatch.observer/filing/0001628280-25-046259.json
- Plain text: https://secwatch.observer/filing/0001628280-25-046259.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.